| Biomarker ID | 823 |
| PMID | 22142399 |
| Year | 2011 |
| Biomarker | TDRD1 |
| Biomarker Basis | Expression Based |
| Biomolecule | mRNA |
| Source | Tissue |
| Subjects | Humans |
| Regulation | Upregulated in TMPRSS2-ERG gene fusion (36 fold) compared to benign samples and TMPRSS2-ERG gene fusion compared to non fusion (23 fold). |
| Odds Ratio/Hazard Ratio/Relative Risk | NA |
| Effect on Pathways | Pathways Include:-Gene Expression,Mitotic Prophase, PIWI-interacting RNA (piRNA) biogenesis |
| Experiment | Benign Vs TMPRSS2-ERG gene fusion Vs non-fusion |
| Type of Biomarker | Prognostic |
| Cohort | 48 prostate tissue samples were chosen out of which 37 were further selected such that 17 had TMPRSS2-ERG gene fusion and 20 did not. Validation cohort 29 benign and 72 fusion-negative and 48 fusion-positive tumor samples. GEO Accession: GSE29079. |
| Senstivity | NA |
| Specificity | NA |
| AUC | NA |
| Accuracy | NA |
| Level Of Significance | TMPRSS2-ERG positive tumors compared to normal (p = 1.77*10^-9) and fusion-negative samples (p = 1.51*10^-9) |
| Method Used | RT-PCR |
| Clinical | No |
| Remarks | NA |
| Clinical Trial Number | NA |
| Degree Of Validity | Validated on Independent Patient Cohort |
| Technical Name | TDRD1 |